Vorapaxar in the secondary prevention of atherothrombosis

Tantry, Udaya S.; Liu, Fang; Chen, Gailing; Gurbel, Paul A.

doi:10.1586/14779072.2015.1109447

Cited by 15 publications

(13 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present concise review aims to cover present anti-platelet drugs directed against platelet receptors of current interest, and to discuss future developments. For a more accurate and profound knowledge of specific platelet adhesion receptors (GPIbα, GPVI, integrin α2β1 and GPIIb/IIIa), G-protein coupled receptors (PAR-1, P2Y 12 ) and their signalling pathways as therapeutic targets, the reader is referred to excellent comprehensive reviews (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

Platelet receptors as therapeutic targets: Past, present and future

Jamasbi¹,

Ayabe²,

Goto³

et al. 2017

Thromb Haemost

View full text Add to dashboard Cite

SummaryAnti-platelet drugs reduce arterial thrombosis after plaque rupture and erosion, prevent stent thrombosis and are used to prevent and treat myocardial infarction and ischaemic stroke. Some of them may also be helpful in treating less frequent diseases such as thrombotic thrombocytopenic purpura. The present concise review aims to cover current and future developments of anti-platelet drugs interfering with the interaction of von Willebrand factor (VWF) with glycoprotein (GP) Ibα, and directed against GPVI, GPIIb/IIIa (integrin α IIb β 3 ), the thrombin receptor PAR-1, and the ADP receptor P2Y 12 . The high expectations of having novel antiplatelet drugs which selectively inhibit arterial thrombosis without interfering with normal haemostasis could possibly be met in the near future.

show abstract

Section: Introductionmentioning

confidence: 99%

Platelet receptors as therapeutic targets: Past, present and future

Jamasbi¹,

Ayabe²,

Goto³

et al. 2017

Thromb Haemost

View full text Add to dashboard Cite

show abstract

“…This appears to be a common feature in different animal models of diabetes. This conclusion is of a great importance and especially when taking into account that inhibitors of PARs consist a new family of antiplatelet drugs . It also has the implication that mice with 3‐month STZ‐induced diabetes constitute a relevant model to study the efficacy of PAR‐4 inhibitors in ameliorating platelet hyperreactivity in animal models of metabolic disorders.…”

Section: Discussionmentioning

confidence: 98%

Effects of three‐month streptozotocin‐induced diabetes in mice on blood platelet reactivity, COX‐1 expression and adhesion potential

Przygodzki

Kassassir

Talar

et al. 2019

Int J Experimental Path

View full text Add to dashboard Cite

Diabetes is associated with an increased risk of cardiovascular disease. This is partially attributed to an altered activation status of blood platelets in this disease. Previously, alterations have been shown in COX-1 and protease activated receptor (PAR)-3 receptor expression in platelets in two animal models of diabetes, there have not been studies which address expression of these proteins in mice with long-term streptozotocin (STZ)-induced diabetes. We have also addressed the effect of diabetes on platelet adhesion under flow conditions. With the use of flow cytometry, we have shown that certain markers of platelet basal activation, such as active form of α IIb β 3 and of CD40L were increased in STZ-induced diabetic mice. Platelets from STZ-induced diabetic mice were also more reactive when stimulated with PAR-4 activating peptide as revealed by higher expression of active form of α IIb β 3 , membrane-bound on vWillebrand Factor and binding of exogenous fluorescein isothyanate-labelled fibrinogen.Expression of COX-1 and production of thromboxane A 2 in platelets of STZ-induced diabetic mice were higher than in control animals. We observed no effect of diabetes on ability of platelets to form stable adhesions with fibrinogen in flow conditions. We conclude that although certain similarities exist between patterns of activation of platelets in animal models of diabetes, the differences should also be taken into account. K E Y W O R D Scell adhesion, diabetes, platelets, prostanoids 42 | PRZYGODZKI et al.

show abstract

“…The current analysis was based on clinical outcomes associated with the use of antiplatelet therapies in the secondary prevention of CV events post-MI. Six CV outcomes commonly used in benefit-risk assessment of antithrombotic treatments were selected: CV mortality, excluding fatal bleeds; nonfatal MI; nonfatal ischemic stroke (IS); nonfatal intracranial hemorrhage (ICH); severe nonfatal, non-ICH bleeds; and fatal bleeding [32,33]. Antithrombotic drugs are used for secondary prevention for their benefit of decreasing the patients' risks of CV mortality, nonfatal MI, and nonfatal IS, although they also increase the risk of bleeding outcomes.…”

Section: Methodsmentioning

confidence: 99%

Net clinical benefit of antiplatelet therapy was affected by patient preferences: A personalized benefit-risk assessment

Tervonen

Prawitz²,

Chua³

et al. 2022

Journal of Clinical Epidemiology

View full text Add to dashboard Cite

Objectives: To assess the effect of patient preferences on the net clinical benefit (NCB) of an antiplatelet therapy for the secondary prevention of cardiovascular complications.Study Design and Setting: Risk equations were developed to estimate the individual predicted risk of key outcomes of antiplatelet treatment in patients with a prior myocardial infarction using the Clinical Practice Research Datalink linked to the Hospital Episode Statistics and UK Office of National Statistics databases. Patient preferences for outcomes of antiplatelet therapies were elicited in a separate discrete choice experiment survey. Trial hazard ratios, relative to placebo, were used to calculate the per-patient NCB using equal or preference weighting of outcomes.Results: Risk equations were estimated using 31,941 adults in the Clinical Practice Research Datalink population, of which 22,125 were included in the benefit-risk assessment. The mean NCB was lower in the preference-weighted than in the equal-weighted analysis (0.040 vs. 0.057; P < 0.0001), but the direction of effect was unchanged by the weighting. In analyses stratified by the presence of bleeding risk factors, including preference weighting altered the ranking of subgroups by NCB.Conclusion: Patient preference weighting may have a significant effect on NCB and should be included in personalized benefit-risk assessments.

show abstract

Vorapaxar in the secondary prevention of atherothrombosis

Cited by 15 publications

References 43 publications

Platelet receptors as therapeutic targets: Past, present and future

Platelet receptors as therapeutic targets: Past, present and future

Effects of three‐month streptozotocin‐induced diabetes in mice on blood platelet reactivity, COX‐1 expression and adhesion potential

Net clinical benefit of antiplatelet therapy was affected by patient preferences: A personalized benefit-risk assessment

Contact Info

Product

Resources

About